Phelan-McDermid Syndrome Clinical Trial
Official title:
Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment
The purpose of this study is to determine whether a relationship exists between gene deletion(s) specific to the mitochondrial electron transport chain and presentation of clinical characteristics in patients with Phelan-McDermid Syndrome (PMS).
Phelan-McDermid Syndrome (PMS) results from a deletion within the 22q13 chromosome region. Most children have specific physical morphology and developmental delays with many displaying characteristics of autism spectrum disorder (ASD) including abnormalities in social development. The behavioral aspect of PMS that parallels ASD has raised particular interest as the SHANK3 gene, which lies in the 22q13 region, is important for synaptic development, and animal SHANK3 knockout models demonstrate ASD characteristics thereby confirming the importance of this gene in PMS. However, despite the importance of the SHANK3 gene, individuals with PMS have variations in their development, behavior and medical characteristics that cannot be fully explained by the SHANK3 deletion. Recently, Frye (2012) has noted the existence of 6 mitochondrial genes that lie slightly proximal to the SHANK3 gene within the 22q13 region. These include genes important electron transport change function (SCO2, NDUFA6), mitochondrial DNA (TYMP) and RNA (TRMU) metabolism, fatty acid metabolism (CPT1B) and tricarboxylic acid cycle function (ACO2). Since most Individuals with PMS have deletions that include chromosomal deletion outside of the SHANK3 region, it is very likely that many, if not most, of children with PMS may have deletions in these mitochondrial genes. Many of these genes have been linked to mitochondrial disease, even in the heterozygous state. Even if recognized, mitochondrial disease is only linked to a homozygous abnormal state (autosomal recessive), the loss of one gene (heterozygous state) could result in symptomatology when associated with deletions in other mitochondrial or non-mitochondrial genes. Abnormalities in mitochondrial pathways can result in neurologic and non-neurologic symptoms including those sometimes seen in children with PMS. Added with the SHANK3 deletion, abnormalities in these mitochondrial genes could explain variations in patterns of development and the eventual cognitive potential. References: Frye RE. Mitochondrial disease in 22q13 duplication syndrome. J Child Neurol. 2012; 27(7):942-9. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT03493607 -
AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy
|
Phase 2 | |
Completed |
NCT03426059 -
Mapping the Phenotype in Adults With Phelan-McDermid Syndrome
|
||
Recruiting |
NCT02461420 -
Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
|
||
Enrolling by invitation |
NCT04312152 -
Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.
|
N/A | |
Completed |
NCT05105685 -
Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05187377 -
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
|
Phase 2 | |
Completed |
NCT01525901 -
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
|
Phase 2 | |
Active, not recruiting |
NCT05025241 -
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
|
Phase 2 | |
Completed |
NCT02710084 -
Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome
|
Phase 2 |